BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yaghoubi Naei V, Monkman J, Sadeghirad H, et al. (2024) Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival. Clinical & Translational Immunology. 13: e1522 |
| Yaghoubi Naei V, Ivanova E, Mullally W, et al. (2024) Characterisation of circulating tumor-associated and immune cells in patients with advanced-stage non-small cell lung cancer. Clinical & Translational Immunology. 13: e1516 |
| Ahmed M, Wuethrich A, Constantin N, et al. (2023) Liquid Biopsy Snapshots of Key Phosphoproteomic Pathways in Lung Cancer Patients for Diagnosis and Therapy Monitoring. Analytical Chemistry |
| Paz-Ares LG, Ciuleanu T, Pluzanski A, et al. (2022) Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Sadeghi Rad H, Bahrami T, Layeghi SM, et al. (2022) Immunotherapeutic targets in non-small cell lung cancer. Immunology |
| Shiravand Y, Khodadadi F, Kashani SMA, et al. (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology (Toronto, Ont.). 29: 3044-3060 |
| Brims FJ, McWilliams A, Harden SV, et al. (2022) Lung cancer: progress with prognosis and the changing state of play. The Medical Journal of Australia. 216: 334-336 |
| Herath S, Sadeghi Rad H, Radfar P, et al. (2022) The Role of Circulating Biomarkers in Lung Cancer. Frontiers in Oncology. 11: 801269 |
| Malapelle U, Pisapia P, Addeo A, et al. (2021) Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert Review of Molecular Diagnostics. 1-14 |
| Kulasinghe A, O'Leary C, Monkman J, et al. (2021) The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 160: 73-77 |